- Conditions
- Melanoma (Skin)
- Interventions
- human gp100 plasmid DNA vaccine, mouse gp100 plasmid DNA vaccine
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 1,829
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
- Interventions
- DUVAX 200 µg, DUVAX 400 µg, Placebo (Adjuvant only)
- Biological
- Lead sponsor
- Nuravax, Inc.
- Industry
- Eligibility
- 40 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Miami Lakes, Florida
- Conditions
- Staphylococcus Aureus
- Interventions
- NDV-3A, Placebo
- Biological
- Lead sponsor
- NovaDigm Therapeutics, Inc.
- Industry
- Eligibility
- 17 Years to 35 Years · Male only
- Enrollment
- 382 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Fort Benning, Georgia
- Conditions
- HIV Infections, HIV Seronegativity
- Interventions
- gp160 Vaccine (Immuno-AG)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 1997
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Seattle, Washington
- Conditions
- Influenza
- Interventions
- Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 4
- States / cities
- Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
- Conditions
- Influenza
- Interventions
- FluBlok Influenza Vaccination, TIV (Fluzone) Influenza Vaccination
- Biological
- Lead sponsor
- Protein Sciences Corporation
- Industry
- Eligibility
- 50 Years to 64 Years
- Enrollment
- 602 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 5
- States / cities
- Fresno, California • Hayward, California • Roseville, California + 2 more
- Conditions
- Malaria
- Interventions
- RTS,S/AS01E, RTS,S/AS01B, Sporozoite-infected mosquitoes challenge.
- Biological · Procedure
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Inflammatory Bowel Disease
- Interventions
- Gardasil vaccine
- Biological
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 9 Years to 26 Years · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- DCVAC/PCa, Placebo
- Biological
- Lead sponsor
- SOTIO a.s.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 58
- States / cities
- Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 52 more
- Conditions
- Ebola Disease, Immunisation
- Interventions
- ChAd3-EBO-Z, MVA Multi-Filo Ebola Vaccine, Placebo
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Plague Vaccine
- Interventions
- rF1V vaccine (with Adjuvant), rF1V vaccine (without Adjuvant)
- Biological
- Lead sponsor
- DynPort Vaccine Company LLC, A GDIT Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 402 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 11
- States / cities
- San Francisco, California • Santa Ana, California • Lenexa, Kansas + 8 more
- Conditions
- HIV Infections
- Interventions
- SAAVI DNA-C2 vaccine, SAAVI MVA-C vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2013
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Influenza, Human
- Interventions
- Flu Pandemic mRNA_Dose level 1, Flu Pandemic mRNA_Dose level 2, Flu Pandemic mRNA_ Dose level 3., Flu Pandemic mRNA_ Dose level 4, Flu Pandemic mRNA_Dose level 5, Flu Pandemic mRNA_Dose level 6, Influenza virus vaccine, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 991 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 21
- States / cities
- Anniston, Alabama • Little Rock, Arkansas • Fort Collins, Colorado + 18 more
- Conditions
- HIV Infections
- Interventions
- BG505 SOSIP.664 gp140, adjuvanted, Placebo
- Biological
- Lead sponsor
- International AIDS Vaccine Initiative
- Network
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Seattle, Washington
- Conditions
- Colorectal Cancer
- Interventions
- PolyPEPI1018 CRC Vaccine
- Biological
- Lead sponsor
- Treos Bio Zrt
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- HIV Infections, Meningitis
- Interventions
- Quadrivalent meningococcal conjugate vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 24 Years
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 35
- States / cities
- Alhambra, California • Long Beach, California • Los Angeles, California + 25 more
- Conditions
- COVID-19
- Interventions
- SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series), Placebo, SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination, SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23,670 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Rolling Hills Estates, California + 20 more
- Conditions
- Melanoma
- Interventions
- melanoma GVAX, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- VXA-RSV-f Tablets (high dose), VXA Placebo Tablets, VXA-RSV-f Tablets (low dose)
- Biological · Other
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Melbourne, Florida
- Conditions
- Influenza
- Interventions
- Influenza VLP Vaccine, TIV
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 467 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 6
- States / cities
- Pembroke Pines, Florida • Rochester, Minnesota • Providence, Rhode Island + 3 more
- Conditions
- Staphylococcal Infections, Joint Prosthesis
- Interventions
- S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate, placebo
- Biological
- Lead sponsor
- Nabi Biopharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Influenza
- Interventions
- Auto-injector for IM/SC vaccine administration
- Device
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2006
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Melanoma (Skin), Intraocular Melanoma
- Interventions
- Xenogeneic Tyrosinase DNA Vaccine, TriGrid Delivery System for Intramuscular Electroporation
- Biological · Device
- Lead sponsor
- Ichor Medical Systems Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease
- Interventions
- INO-4800, CELLECTRA® 2000, Placebo
- Drug · Device
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,307 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 16
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 12 more